WaymackJP, Miskell P, Gonce S. Anesth Analg 69:163-198, 1989. 27. W 19 a8y7m . ackJP, Warden GD, Alexander JW, Miskell P, Gonce S. J Surg Res 42:528-535, 28. JWSauyrmgaRceksJP4 , 9 M :3 o2l8d -a 3 w 32 er , L 19 L 9 , 0 L . owry SF, Guzman RF, Okerberg CV, Mason AD, Pruitt BA. 29. WaymackJP and Yurt RW. J Surg Res 48:147-143, 1990. 30. AWnanym Su arcgk JP, 20M4( c6N ): e6a8l1N -6 , 8W5, a 1 rd 9e8n6 . GD, Balakrishnan K, Gonce S, Alexander JW, Miskell P. 31. W BA aJyrm . aAcrkcJhPS , u H rg e rn 1a2n6d : e5z9 -G 62 , , C1a9p9p1e . lli PJ, Burleson DG, Guzman RF, Mason AD Jr, Pruitt 32. Gantt CL. Lancet ii:363, 1981. 33. Chung M, Steionmetz OK, Gordon PH. BrJ Surg 80:427-432, 1993. 34. W 19 e9i2 ss . MM, Jauch KW, Delanoff CL, Memple W, Schildberg FW. Proc ASCO 11:172, 35. H Si anaggh , 1S9K8 . 8. The Blood Bank, Rotterdam: Cip - Gegevens Koninklijke Bibiliotheek, Den 36. Taylor C and Faulk WP. Lancet ii:68-69, 1981. 37. Peters WR, Fry RD, Fleshman JW, Kodner IJ. Dis Col & Rect 32(9):749-753, 1989. 38. Williams JG and Hughes LE. Lancet H31-132, 1989. 39. SGta eu st proW en H te , roBl ra SnudpA pl , 2W6: e 8 te 1 r -m 86 a , n1I9T9 , 1 . Zwinderman KH, Lamers CBHW, Gooszen. Scand J 40. Scott ADN, Ritchie JK, Phillips RKS. BrJ Surg 78:455-4587, 1991. 41. Tadros Tamer, Wobbes T, Hendriks T. Ann Surg 215(3):276-281, 1992. 42. R 74 o : s3s9 in -i 46A , A 1 , 9 F 84 a . ustman D, Woda BA, Like AA, Szymanski I, Mordes JP. J Clin Invest 43. Tartter PI, Heimann TM, Aufses AH Jr. Am J Surg 151: 358, 1986. 44. T ca anrc tt eerrpPaIt . i en Ttrsa . ns V fu osxioSnanhg is to 5r6y : , 80T , c1e9l8l9s . ub sets and natural killer cytotoxicity in colorectal 45. Beck I, Scott JS, Pepper M, Speck EH. Am J Repro Immunol 1:224, 1981. 46. Tartter PI. Transfusion 28:593-596, 1988.

ABSTRACT

Experimental evidence is accumulating to support a central role for cytokines in the pathophysiology of hemolytic transfusion reactions. The production of tumor necrosis factor, interleukin-8, and monocyte chemoattractant protein occurs in whole blood in response to ABO incompatible red cells, a model of acute hemolytic transfusion reactions. Peripheral blood mononuclear cells may produce interleukin-ΐβ, tumor necrosis factor, interleukin-8, monocyte chemoattractant protein, and interleukin-1 receptor antagonist in response to IgG-coated red cells, a model of delayed hemolytic transfusion reactions. Cultured umbilical vein endothelial cells respond to conditioned plasma from ABO-incompatibility reactions by expressing the procoagulant tissue factor and the leukocyte adhesion molecules ELAM-1 and ICAM-1. These in vitro endothelial cell responses can be inhibited by neutralizing antibodies to tumor necrosis factor, suggesting that TNF may have a central role in intravascular coagulation and end-organ injury that may occur in acute hemolytic transfusion reactions.